Hypersensitivity to liraglutide: A case report.

Saxenda (liraglutide) is approved for the treatment of type 2 diabetes mellitus and chronic weight management in adults with obesity. We present the case of a 44-year-old woman with grade 2 obesity who was treated with liraglutide for weight reduction, initially well-tolerated. Despite a brief pause in liraglutide treatment for 5 days due to hospitalization, she developed, after the reintroduction of this treatment, a localized reaction characterized by maculopapular erythema and pruritus at the injection site. Skin tests revealed an acute positive reaction to liraglutide. Literature suggests variability in allergic reactions among glucagon-like peptide-1 receptor agonists, highlighting the need for further research. Our case underscores the importance of individualized management in treating adverse reactions to liraglutide in obese patients without type 2 diabetes mellitus.